No abstract available.
Mediastinum*

No abstract available.
Kidney* ; Perfusion* ; Radionuclide Imaging*

No abstract available.
Arachnoid*

No abstract available.
Dipyridamole* ; Tomography, Emission-Computed, Single-Photon*

No abstract available.
Captopril* ; Diagnosis* ; Hypertension, Renovascular* ; Radionuclide Imaging*

No abstract available.
Gallium* ; Lymphoma*

No abstract available.
Antibodies* ; Cerebellar Ataxia ; Guillain-Barre Syndrome* ; Humans

Fitz-Hugh-Curtis (FHC) syndrome is hepatitis characterized by severe right upper abdominal pain associated with pelvic inflammatory disease (PID), mimicking the symptoms of acute abdomen, such as in acute cholecystitis. FHC syndrome is becoming more common with the increasing incidence of PID in Korea. We treated eight patients with FHC syndrome, who visited our hospital with right upper quadrant abdominal pain. We emphasize the importance of spiral computed tomography (CT) in the diagnosis of right upper quadrant abdominal pain in sexually active young women.
Abdomen, Acute ; Abdominal Pain ; Chlamydia Infections ; Cholecystitis, Acute ; Female ; Hepatitis ; Humans ; Incidence ; Korea ; Pelvic Inflammatory Disease ; Peritonitis ; Tomography, Spiral Computed

BACKGROUND AND OBJECTIVES: Because the mechanisms of the biological effects of statin and antiotensin converting enzyme inhibitor therapies differ, the vascular responses to these therapies were studied in hypercholesterolemic patients. MATERIALS AND METHODS: Simvastatin, 20 mg, placebo or ramipril, 10 mg, were administered daily for 2 months, with a 2 month washout, to 32 hypercholesterolemic patients. This was a randomized, double-blind, placebo-controlled, crossover in design study. RESULTS: Simvastatin alone, or in combination with ramipril, significantly changed the lipoproteins, and improved the percentage of the flow-mediated dilator response to hyperemia by 46+/-48% and by 59+/-66%, respectively, relative to the baseline measurements (both p<0.001). The plasma malondialdehyde levels were reduced, relative to baseline measurements, by 6+/-57% (p=0.045) and 13+/-47% (p=0.045 and p<0.001, respectively) and plasma levels of monocyte chemoattractant protein-1 by 3+/-27% and by 9+/-16%, respectively (p=0.113 and p=0.001, respectively). The C-reactive protein were also reduced, relative to baseline measurements, by 17+/-75% and by 17+/-37%, respectively (p=0.003 and p=0.001, respectively). However, simvastatin combined with ramipril changed, to a greater extent, but was statistically insignificant, the percentage of the flow-mediated dilator response to hyperemia, and the plasma monocyte chemoattractant protein-1 levels, than simvastatin alone. CONCLUSION: Compared with simvastatin alone, the addition of ramipril improved the endothelial function to greater extent, but was statistically insignificant, in hypercholes-terolemic patients.
C-Reactive Protein ; Chemokine CCL2 ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hyperemia ; Inflammation* ; Lipoproteins ; Malondialdehyde ; Nitric Oxide* ; Plasma ; Ramipril* ; Simvastatin*

No abstract available.
Child* ; Humans ; Technetium Tc 99m Dimercaptosuccinic Acid* ; Vesico-Ureteral Reflux*